Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Centogene

Nasdaq:CNTG
Snowflake Description

Limited growth and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CNTG
Nasdaq
$317M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Centogene B.V. operates as a commercial-stage rare disease company worldwide. The last earnings update was 114 days ago. More info.


Add to Portfolio Compare Print
  • Centogene has significant price volatility in the past 3 months.
CNTG Share Price and Events
7 Day Returns
-24.1%
NasdaqGM:CNTG
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-
NasdaqGM:CNTG
0%
US Biotechs
-11.5%
US Market
CNTG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Centogene (CNTG) -24.1% 39.7% 62.4% - - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • No trading data on CNTG.
  • No trading data on CNTG.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Centogene undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Centogene. This is due to cash flow or dividend data being unavailable. The share price is $15.98.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Centogene's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Centogene's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:CNTG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in EUR €-59.29
NasdaqGM:CNTG Share Price ** NasdaqGM (2020-03-27) in USD $15.98
NasdaqGM:CNTG Share Price converted to EUR reporting currency Exchange rate (USD/ EUR) 0.902 €14.41
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Centogene.

NasdaqGM:CNTG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CNTG Share Price ÷ EPS (both in EUR)

= 14.41 ÷ -59.29

-0.24x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Centogene is loss making, we can't compare its value to the US Biotechs industry average.
  • Centogene is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Centogene's expected growth come at a high price?
Raw Data
NasdaqGM:CNTG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.24x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
1.1%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Centogene, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Centogene's assets?
Raw Data
NasdaqGM:CNTG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in EUR €37.58
NasdaqGM:CNTG Share Price * NasdaqGM (2020-03-27) in USD $15.98
NasdaqGM:CNTG Share Price converted to EUR reporting currency Exchange rate (USD/ EUR) 0.902 €14.41
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:CNTG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CNTG Share Price ÷ Book Value per Share (both in EUR)

= 14.41 ÷ 37.58

0.38x

* Primary Listing of Centogene.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Centogene is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Centogene's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Centogene has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Centogene expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
1.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Centogene expected to grow at an attractive rate?
  • Unable to compare Centogene's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Centogene's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Centogene's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:CNTG Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:CNTG Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 1.1%
NasdaqGM:CNTG Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 23.3%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:CNTG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:CNTG Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 123 1
2022-12-31 102 1
2021-12-31 79 7 -19 4
2020-12-31 63 1 -20 4
2020-03-28
2019-12-31 49 -1 -19 3
NasdaqGM:CNTG Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-09-30 44 -4 -19
2019-06-30 45 -3 -16
2019-03-31 43 -4 -14
2018-12-31 40 -5 -11
2018-09-30 39 -4 -9
2017-12-31 32 -4 -5
2016-12-31 28 1 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Centogene is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Centogene's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:CNTG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Centogene Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CNTG Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 -0.91 -0.58 -1.17 4.00
2020-12-31 -0.99 -0.92 -1.09 4.00
2020-03-28
2019-12-31 -2.74 -1.00 -3.67 3.00
NasdaqGM:CNTG Past Financials Data
Date (Data in EUR Millions) EPS *
2019-09-30 -59.29
2019-06-30 -51.73
2019-03-31 -45.94
2018-12-31 -39.57
2018-09-30 -28.87
2017-12-31 -22.32
2016-12-31 -25.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Centogene will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Centogene's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Centogene has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Centogene performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Centogene's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Centogene does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Centogene's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Centogene's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Centogene's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Centogene Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CNTG Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 43.65 -19.33 29.55 8.64
2019-06-30 45.39 -16.28 30.17 8.05
2019-03-31 42.93 -13.81 28.12 7.18
2018-12-31 40.48 -11.34 26.08 6.30
2018-09-30 39.15 -8.84 22.80 7.33
2017-12-31 31.69 -5.48 15.40 6.40
2016-12-31 27.67 -5.36 14.25 5.89

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Centogene has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Centogene has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Centogene improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Centogene's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Centogene has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Centogene's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Centogene's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Centogene's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Centogene's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Centogene's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Centogene Company Filings, last reported 5 months ago.

NasdaqGM:CNTG Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 11.19 6.29 6.06
2019-06-30 15.46 17.55 3.56
2019-03-31 15.46 17.55 3.56
2018-12-31 26.52 16.62 9.22
2018-09-30 20.21 18.11 1.97
2017-12-31 16.35 15.84 3.16
2016-12-31 2.74 14.60 0.97
  • Centogene's level of debt (56.2%) compared to net worth is high (greater than 40%).
  • Unable to establish if Centogene's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Centogene has less than a year of cash runway based on current free cash flow.
  • Centogene has less than a year of cash runway if free cash flow continues to reduce at historical rates of -2.1% each year.
X
Financial health checks
We assess Centogene's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Centogene has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Centogene's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Centogene dividends.
If you bought $2,000 of Centogene shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Centogene's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Centogene's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:CNTG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:CNTG Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Centogene has not reported any payouts.
  • Unable to verify if Centogene's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Centogene's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Centogene has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Centogene's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Centogene afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Centogene has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Centogene's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Arndt Rolfs
COMPENSATION €1,413,000
AGE 60
TENURE AS CEO 6.2 years
CEO Bio

Prof. Arndt Rolfs, MD, is a co-founder of Centogene N.V. and has served as Chief Executive Officer since 2014 and Chief Medical Officer since 2006. Prof. Rolfs serves as a Member of Management Board of Centogene N.V. Prof. Rolfs has been the Chief Executive Officer and Founder at Centogene AG and had served as its Chief Medical Director. Prof. Rolfs is a Professor of Neurology and Psychiatry at the University of Rostock, Germany and head of the Albrecht-Kossel-Institute for Neuroregeneration. He serves as Medical Director at Vivendy Therapeutics Ltd. After his approbation for human medicine in 1985, he worked at the Department of Neurology and as head of the Laboratory for Neurochemistry of the Free University of Berlin, at the Max Planck Institute for Molecular Genetics and at the psychiatric clinic of the University Hospital Rudolf-Virchow in Berlin. Prof. Rolfs has been working for the University of Rostock since 1993, initially as senior consultant at the Department of Neurology and head of the Neurobiology Laboratory, later on as vice director of the Clinic and Outpatients Department for Neurology at the Centre for Neurology and as Professor for Neurology. Prof. Rolfs is a principal investigator of several international multicentre studies in the area of rare diseases, such as the Sifap project (the world's largest study in young stroke patients). Since 1991 he acts as a consultant for international biotech and industrial companies and is a co-founder of Arcensus AG (Berlin, 2001), Genebanking AG (Berlin, 2001) and Centogene GmbH (Rostock, 2005.) He has been the Director of the Albrecht-Kossel-Institute for Neuroregeneration at the University of Rostock since 2008. He serves as Member of the Supervisory Board at Centogene AG. Prof. Rolfs obtained his degree at the Universities of Mainz, Germany and Vienna, Austria.

CEO Compensation
  • Insufficient data for Arndt to compare compensation growth.
  • Arndt's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Centogene management team in years:

0.8
Average Tenure
52
Average Age
  • The average tenure for the Centogene management team is less than 2 years, this suggests a new team.
Management Team

Arndt Rolfs

TITLE
Founder
COMPENSATION
€1M
AGE
60
TENURE
6.2 yrs

Richard Stoffelen

TITLE
CFO & Member of Management Board
COMPENSATION
€1M
AGE
52
TENURE
4.2 yrs

Dirk Ehlers

TITLE
COO, President of Clinical Diagnostics & Member of Management Board
COMPENSATION
€1M
AGE
58

Volkmar Weckesser

TITLE
Chief Information Officer & Member of Management Board
COMPENSATION
€1M
AGE
52

Philip Lambert

TITLE
Chief Scientific Officer
TENURE
0.2 yrs

Christoph Artiagoitia

TITLE
Senior Vice President of Finance & Administration
TENURE
0.2 yrs

Sun Kim

TITLE
Chief Strategy & Investor Relations Officer
AGE
47
TENURE
0.8 yrs

Frank Volpers

TITLE
Vice President of Legal

Ross Bethell

TITLE
Director of Corporate Communication

Robert de Deugd

TITLE
Senior Vice President of Sales
Board of Directors Tenure

Average tenure and age of the Centogene board of directors in years:

3.2
Average Tenure
60
Average Age
  • The tenure for the Centogene board of directors is about average.
Board of Directors

Flemming Ornskov

TITLE
Chairman of the Supervisory Board
AGE
61
TENURE
0.9 yrs

Hubert Birner

TITLE
Vice Chairman of the Supervisory Board
COMPENSATION
€47K
AGE
53

Christoph Ehlers

TITLE
Member of the Supervisory Board
COMPENSATION
€45K
AGE
61
TENURE
6.2 yrs

Holger Friedrich

TITLE
Member of the Supervisory Board
COMPENSATION
€23K
AGE
52
TENURE
3.2 yrs

Guido Prehn

TITLE
Member of the Supervisory Board
COMPENSATION
€44K
AGE
40
TENURE
3.2 yrs

Eric Souêtre

TITLE
Member of the Supervisory Board
COMPENSATION
€28K
AGE
63
TENURE
3.2 yrs

Berndt A. Modig

TITLE
Member of the Supervisory Board
COMPENSATION
€52K
AGE
60
TENURE
1.9 yrs

Daniel Parera

TITLE
Supervisory Director
COMPENSATION
€27K
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
14. Feb 20 Buy Careventures S.A. Company 12. Nov 19 12. Nov 19 142,857 $14.00 $1,999,998
14. Jan 20 Buy TVM Capital GmbH Company 12. Nov 19 12. Nov 19 857,142 $14.00 $11,999,988
22. Nov 19 Buy DPE Deutsche Private Equity GmbH Company 12. Nov 19 12. Nov 19 1,000,000 $14.00 $14,000,000
X
Management checks
We assess Centogene's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Centogene has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene B.V. was founded in 2006 and is headquartered in Rostock, Germany.

Details
Name: Centogene N.V.
CNTG
Exchange: NasdaqGM
Founded: 2006
$317,384,213
19,861,340
Website: http://www.centogene.com
Address: Centogene N.V.
Am Strande 7,
Rostock,
Mecklenburg-Western Pomerania, 18055,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CNTG Common Shares Nasdaq Global Market US USD 05. Nov 2019
DB 39K Common Shares Deutsche Boerse AG DE EUR 05. Nov 2019
MUN 39K Common Shares Boerse Muenchen DE EUR 05. Nov 2019
Number of employees
Current staff
Staff numbers
400
Centogene employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:42
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/02/25
Last earnings filing: 2019/12/05
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.